Connect with us

Technology

ivWatch: Innovative Technology Now Available Through UK NHS Supply Chain

Published

on

Disruptive innovation provides NHS Trusts faster access to continuous IV monitoring to reduce avoidable extravasation harm

NEWPORT NEWS, Va. and LONDON, July 22, 2026 /PRNewswire/ — ivWatch, the IV safety company, today announced that its continuous IV site monitoring system has been selected for inclusion in the NHS Supply Chain Innovation Products pathway. While inclusion in national procurement pathways can take years, ivWatch progressed through the Innovation Products review process on an expedited basis, enabling NHS organisations across the United Kingdom to access its advanced technology through a compliant and streamlined procurement route.

The Innovation Products Pathway makes it easier for NHS Trusts to adopt clinically proven technologies that solve persistent patient safety problems. With ivWatch now approved on this pathway, NHS Trusts have a ready-to-implement solution to proactively address IV infiltration and extravasation – complications that result in preventable harm, claims exposure, and treatment delays. Trusts evaluating strategies to reduce IV-related harm no longer need to navigate procurement barriers to implement continuous monitoring. This sole award of ivWatch to the NHSSC framework, marks a key milestone in a national strategic initiative to accelerate access to peripheral IV site monitoring technology for safer care across NHS England.

ivWatch provides continuous, non-invasive monitoring of tissue adjacent to a peripheral IV insertion site. Using patented optical sensing and a predictive algorithm, the system is designed to detect the earliest signs of IV infiltration and extravasation – complications where IV fluids leak into surrounding tissue and can lead to pain, tissue damage, delayed treatment, and, in severe cases, long-term harm. Early detection helps clinicians intervene sooner, reducing the risk of injury, improving outcomes, and lowering avoidable costs to the hospital.

Maya Aquino-Guerrero, Patient Safety Champion at NHS Supply Chain and NIVAS Board Member, said, “In my ongoing efforts to elevate patient safety standards across the NHS, I’ve seen firsthand how early detection technologies like ivWatch can transform IV care. Extravasation injuries are not only painful, but often avoidable with timely intervention. ivWatch’s ability to provide continuous, real-time monitoring empowers clinicians to act quickly, preventing harm and reducing costly complications. This technology embodies the kind of innovation we need to protect patients and ensure the best use of NHS resources.”

Aquino-Guerrero recently presented this approach at the World Congress on Vascular Access (WoCoVA), where she shared a poster on global platform, an NHS initiative to accelerate access to continuous peripheral IV site monitoring technology across England. The work highlights how earlier detection can reduce the severity of injuries, take pressure off clinical staff, and deliver systemwide cost savings.

The poster outlines a structured pathway from pilot implementation to broader scale adoption, with initial expansion anticipated over an 18‑month period.1

Transforming patient safety across the NHS

Peripheral IV therapy ranks among the most common procedures in NHS hospitals, yet infiltration and extravasation remain significantly under-recognised contributors to patient harm. Conventional visual and manual assessments frequently miss early tissue changes, particularly when IV sites are obscured or patients cannot communicate pain, leading to adverse events.

Clinical evaluations referenced by NHS Supply Chain indicate that continuous monitoring technologies such as ivWatch can play an important role in reducing the severity of IV-related harm, improving workflow efficiency, and supporting safer delivery of high-risk infusions across adult and paediatric populations.

Clinical leadership driving adoption

Central to ivWatch’s success in the NHS has been Andrew Barton, Nurse Consultant in IV Therapy and Vascular Access at Frimley Health NHS Foundation Trust and Chairman of the National Infusion and Vascular Access Society (NIVAS), who has championed the clinical trial and implementation of ivWatch technology in UK clinical settings. In the study he oversaw, the ivWatch system detected infiltration and extravasation events earlier than relying on intermittent visual observation alone, and detection occurred in 100% of IV infiltration events before a clinician could visually detect the event.

Under Barton’s leadership, ivWatch has been deployed for over two years within NHS units with strong results of no IV extravasation injuries, strengthening clinical confidence in the delivery of IV therapy safety. His work was recently recognised with the HSJ Patient Safety Pilot Program of the Year award, reflecting both the clinical effectiveness of the technology and Barton’s leadership in advancing patient safety throughout the NHS. Barton is also the creator of the NIVAS Extravasation Toolkit, which is preventing devastating severe IV injuries in the UK and around the globe.

“Spearheading the ivWatch initiative has been a game-changer for our IV therapy practice,” said Barton. “We have witnessed a remarkable reduction in extravasation incidents, improving patient safety and staff confidence. The expeditious process of the NHS Supply Chain Innovation Products pathway underscores the urgency and tangible impact of ivWatch. This technology not only safeguards our patients, but also supports our commitment to innovation and excellence in care.”

A pathway to broader adoption through NHS supply chain

With its addition to the Innovation Products portfolio, ivWatch monitors, sensors, and clinical support materials are now accessible to NHS organisations – from acute Trusts to specialty units – through NHS Supply Chain’s established procurement infrastructure. This gives NHS Trusts a direct route to adopt innovative technology to address longstanding IV safety challenges across multiple pathways including systemic anti-cancer therapy, non-chemotherapy infusions such as iron and antibiotics, acute and emergency care, critical care, paediatrics, and vascular access services.

ivWatch will continue to work with NHS clinicians and stakeholders to support ongoing education, evidence generation, and implementation, ensuring that teams adopting the technology can maximize patient safety and quality benefits.

About ivWatch

ivWatch is changing IV safety. IV insertion is the most common hospital procedure, yet up to 50% fail, often with severe consequences ranging from dosing errors, scarring, skin staining, nerve damage, amputation, and even death. Founded in 2010 and holding nearly 70 patents, ivWatch has developed a first-of-its-kind FDA-cleared and MDR CE marked Class II medical device that continuously monitors peripheral IVs to aid in the early detection of infiltration and extravasation events. To learn more, visit www.ivwatch.com.

About NHS Supply Chain

NHS Supply Chain manages the sourcing, delivery and supply of healthcare products, services and food for NHS trusts and healthcare organizations across England and Wales.

Their role is to source, deliver and supply healthcare products, services and food for NHS trusts and healthcare organizations across England and Wales. By working in collaboration with the healthcare system and suppliers, they help the NHS to put patients first.

NHS Supply Chain is a part of the NHS and delivers cost-efficient, resilient, clinically assured products that are responsive to frontline needs. They focus on the end-to-end patient pathway which supports the healthcare system to:

Reduce treatment times

Decrease patient length of stay

Enable more care in community settings

Improve clinical outcomes.

References:
1. https://www.ivwatch.com/wp-content/uploads/2026/05/Transforming-patient-safety-a-strategic-initiative-on-accelerating-national-access-to-peripheral-iv-site-monitoring-technology-for-safer-care-across-NHS-EnglandMI-0000012.pdf

View original content to download multimedia:https://www.prnewswire.com/news-releases/ivwatch-innovative-technology-now-available-through-uk-nhs-supply-chain-302831324.html

SOURCE ivWatch, LLC

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Yiren Digital Accelerates Operating Efficiency Through AI Agent Deployment

Published

on

By

Broader AI adoption improves productivity across asset recovery and enterprise operations

BEIJING, July 23, 2026 /PRNewswire/ — Yiren Digital Ltd. (NYSE: YRD) (“Yiren Digital” or the “Company”), a leading company specializing in financial technology and artificial intelligence innovation across multiple industries in China and global markets, today announced measurable operating efficiency improvements as it continues to deploy AI agents across core enterprise workflows. Broader AI adoption is reducing manual intervention, increasing workforce productivity and creating greater operating leverage by automating high-volume processes across multiple business functions.

These deployments are a key component of Yiren Digital’s “All-in-AI” strategy and its broader transition from AI-assisted productivity toward agent-driven execution. By embedding AI agents into core workflows, the Company is creating reusable operating capabilities that can be deployed across its businesses, supporting greater efficiency and reducing the cost of extending automation into new functions.

“Our objective is not simply to automate individual tasks, but to fundamentally improve how work is performed across the enterprise,” said Mr. Ning Tang, Chairman and Chief Executive Officer of Yiren Digital. “As AI agents take on more of our high-volume, demanding workflows, the productivity gains are becoming a structural part of how we run the business, not a one-time efficiency project. We will continue to deepen AI integration across our existing businesses while extending reusable capabilities into additional verticals.”

The AI deployments are supported by the Company’s proprietary enterprise AI architecture, including MagiCube 2.0, its upgraded multi-agent platform. The platform provides common infrastructure for agents deployed across marketing, customer service, capital operations, risk management, compliance and research and development, with more than 10 reusable foundational capabilities, supporting enterprise-wide execution.

Measurable Operating Impact

Lower manual intervention: The human handling rate in asset-recovery operations decreased from 45.0% to 24.9%, representing a 20.1-percentage-point decline, an approximately 44.6% relative reduction in manual intervention.

Higher staff productivity: The number of service tickets handled per asset-recovery staff member within the applicable Month 1 workflow increased from 358 to 525, an improvement of approximately 47%.

Expanded agent adoption: AI agents accounted for 81% of service tickets within eligible Day 1 asset-recovery workflows in 2025, up from 50% in 2024. The Company also deployed AI agents selectively in later-stage workflows, accounting for 20% of eligible service tickets at Day 4, 14% at Day 16 and 20% at Month 2. Each percentage is calculated separately for the relevant stage and should not be interpreted as a sequential adoption trend.

Enterprise-wide reuse: MagiCube 2.0 supports agent deployment across six enterprise functions, allowing the Company to apply common AI capabilities to a broader range of regulated and high-volume workflows.

Enterprise-scale AI execution: The Fengchao AI voice agent processes approximately 1,500 hours of real-time speech-to-text activity each day. The LingShu intelligent marketing platform executes more than 1,700 tasks daily and generates individualized communication content in an average of 0.6 seconds.

Building Enterprise Operating Leverage Through AI

As AI deployment expands across the enterprise, Yiren Digital is increasingly shifting repetitive, high-volume tasks from human-assisted processes toward agent-driven execution. By combining AI agents with centralized orchestration and governance, the Company is improving operating consistency, strengthening workforce productivity and creating reusable capabilities that increase operating leverage as AI is deployed across additional business functions.

Yiren Digital plans to continue expanding agent-driven workflows across its credit and insurance operations, as part of its ongoing All-in-AI strategy, while strengthening the shared architecture and governance that support enterprise-wide AI deployment. These capabilities are designed to scale across multiple use cases and provide a foundation for the Company’s broader expansion into AI application-layer opportunities, including AI entertainment and AI-assisted language learning.

About Yiren Digital

Yiren Digital Ltd. is a leading company specializing in financial technology and artificial intelligence innovation across multiple industries in China and global markets. The Company leverages advanced artificial intelligence and emerging technologies to enhance customer experience, optimize capital efficiency, and expand financial inclusion. Following the regulatory filing of its in-house developed Large Language Model Zhiyu, and the significant enhancement of its MagiCube Agent platform, Yiren Digital is establishing a new growth engine to accelerate its evolution into an AI-native, multi-industry operating platform extending beyond traditional financial services. For more information, please visit https://ir.yiren.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “hope,” “going forward,” “intend,” “ought to,” “plan,” “project,” “potential,” “seek,” “may,” “might,” “can,” “could,” “will,” “would,” “shall,” “should,” “is likely to” and the negative form of these words and other similar expressions. This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident,” and similar expressions. Forward-looking statements are based on management’s current expectations, assumptions, and assessments of current market and operating conditions. These statements involve inherent risks, uncertainties, and other factors, many of which are outside the control of the Company, and which could cause actual results to differ materially from those expressed or implied in such statements. Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements speak only as of the date of this press release. The Company undertakes no, and expressly disclaims any, obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required under applicable law.

View original content:https://www.prnewswire.com/news-releases/yiren-digital-accelerates-operating-efficiency-through-ai-agent-deployment-302833201.html

SOURCE Yiren Digital Ltd.

Continue Reading

Technology

Infinium Edge Launches EdgeSites™, a New Infrastructure Model for Deploying AI Compute at Existing Commercial and Industrial Facilities

Published

on

By

EdgeSites delivers operational AI infrastructure in existing powered buildings — factory-built data center modules, waterless cooling, and ready in months without new construction or grid interconnection required.

SACRAMENTO, Calif., July 23, 2026 /PRNewswire/ — Infinium Edge™ today announced Infinium EdgeSites™, a development program that utilizes existing commercial and industrial facilities to deploy operational AI compute infrastructure. Built around Infinium Edge’s proprietary Edge Thermal Vectoring™ immersion cooling platform, EdgeSites enables high-density GPU deployments in existing buildings that were never designed as data centers — without new construction, without cooling water infrastructure, and without the multi-year grid interconnection timelines that constrain conventional large-scale data center development.

More than 20 million commercial and industrial electricity customers in the US are served by electrical infrastructure sized to peak demand – which industry research shows are utilized at only 40-60% on average. That unused headroom, capacity already contracted, energized, and sitting behind the meter, can support high-density AI compute without adding new load to the grid or waiting on a new interconnection.

At the center of the program is the Vector ONE™ — Edge’s factory-built, self-contained immersion cooling system designed to house 1 MW of AI compute capacity. Vector ONE units are engineered for deployment in standard commercial and industrial buildings, either indoors or outdoors, arriving pre-integrated, fully commissioned and require no municipal water connection. Installations are modular and scalable: additional units can be commissioned as site power and demand allow, without rebuilding the underlying infrastructure and occupy up to 70% less floor space than air-cooled equivalents.

Built for the Shift to Inference

As inference moves to displace training as the dominant AI workload, the growth opportunity is shifting towards small, distributed data centers that can be deployed quickly and sited where demand originates. Conventional data center developments are under compounding pressure from long utility interconnection queues, sometimes lasting years, pressure around water use, and general community and regulatory opposition enacting restrictions. Community opposition and regulatory friction delayed or blocked an estimated $156 billion in planned U.S. data center capacity in 2025 alone.

EdgeSites is purpose-built for the structural shift to inference and addresses key issues stalling conventional data center developments today. Each Vector ONE unit delivers 1 MW of inference-ready capacity inside an existing building, in a market that already has established electrical infrastructure, in a timeline measured in months rather than years. Multiple units can be used in tandem to deploy up to 10 MW of capacity at a single site.  The program converts the distributed inventory of underutilized industrial or commercial electrical capacity in the United States into a nationally scaled inference network. Vector ONE’s dry-cooler loop consumes no municipal water, making EdgeSites viable in markets where evaporative cooling has been restricted or banned.

“The data center industry has been answering an infrastructure shortage with a construction playbook — build new facilities, secure new grid connections, wait years for capacity to come online,” said Robert Schuetzle, CEO of Infinium. “That model cannot keep pace with AI deployment timelines. Infinium EdgeSites operate around different premises: the power already exists, the buildings already exist, and the technology now exists to put them to work. We are making operational what the industry has been treating as stranded.”

Deploying EdgeSites

As demand for AI compute continues to outpace available infrastructure and focuses on distributed inference needs, Infinium Edge is expanding the EdgeSites network with qualified host locations and compute partners.

Commercial and industrial property owners of industrial sites, distribution centers, warehouses, or large commercial properties with available electrical capacity benefit from receiving lease income from infrastructure they already own or control. Infinium Edge manages all aspects of site development and operations for installing and deploying the Vector ONE system. No capital investment or operational responsibility is required from the host.

AI companies, enterprises, and compute operators requiring infrastructure on compressed deployment timelines can access high-density, edge-proximate GPU capacity through a straightforward capacity agreement, priced by the kilowatt-month, with backup power included in the capacity fee. There is no construction to manage, no permitting process to navigate, and no cooling infrastructure to operate or maintain.

Infinium Edge manages the full program from development and installation to operation and monitoring— simplifying development and data center management for AI companies and enterprises.

Reach out to learn more and partner in EdgeSites deployments.

Inquiries: www.infinium.ai/edgesites

About Infinium Edge™
Infinium Edge™ is the advanced AI data center infrastructure platform from Infinium, delivering high-density, sustainable compute through proprietary single-phase immersion cooling technology. Infinium Edge is the only North American producer of Fischer-Tropsch immersion fluids and offers a full-stack platform — including Edge Thermal Vectoring™ platform, Vector ONE™ modular AI Factory units, ETV100 immersion fluids, and integrated monitoring systems — engineered for the thermal and operational demands of AI and high-performance computing at scale. For more information, visit www.infinium.ai.

View original content to download multimedia:https://www.prnewswire.com/news-releases/infinium-edge-launches-edgesites-a-new-infrastructure-model-for-deploying-ai-compute-at-existing-commercial-and-industrial-facilities-302832792.html

SOURCE Infinium

Continue Reading

Technology

ChipMOS SCHEDULES SECOND QUARTER 2026 FINANCIAL RESULTS SEMIANNUAL CONFERENCE CALL

Published

on

By

HSINCHU, July 23, 2026 /PRNewswire-FirstCall/ — ChipMOS TECHNOLOGIES INC. (“ChipMOS” or the “Company”) (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS), an industry leading provider of outsourced semiconductor assembly and test services (“OSAT”), today announced that it will report second quarter 2026 results and host a semiannual conference call after the close of trading on the Taiwan Stock Exchange on Tuesday, August 11, 2026.

Investors and analysts are encouraged to participate in the semiannual conference call using the dial-in phone number noted below. A webcast and replay will be available on the Company’s website.

Date: Tuesday, August 11, 2026
Time: 3:00PM Taiwan (3:00AM New York)
Dial-In: +886-2-3396 1191
Password: 1637011 #

Semiannual Conference Call Webcast and Replay: https://www.chipmos.com/chinese/ir/info2.aspx
Replay: Starts Approximately 2 hours after the live call ends

Language: Mandarin

Note: A transcript will be provided on the Company’s website in English following the semiannual conference call to help ensure transparency, and to facilitate a better understanding of the Company’s financial results and operating environment.

About ChipMOS TECHNOLOGIES INC.:
ChipMOS TECHNOLOGIES INC. (“ChipMOS” or the “Company”) (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS) (www.chipmos.com) is an industry leading provider of outsourced semiconductor assembly and test services. With advanced facilities in Hsinchu Science Park, Hsinchu Industrial Park and Southern Taiwan Science Park in Taiwan, ChipMOS is known for its track record of excellence and history of innovation. The Company provides end-to-end assembly and test services to leading fabless semiconductor companies, integrated device manufacturers and independent semiconductor foundries serving virtually all end markets worldwide.

Forward-Looking Statements:
This press release may contain certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future’ or similar expressions or by discussion of, among other things, strategies, goals, plans or intentions. These statements may include financial projections and estimates and their underlying assumptions, statements regarding current macroeconomic conditions, including the impacts of high inflation, foreign exchange rates and risk of recession, on demand for our products, consumer confidence and financial markets generally; changes in trade regulations, policies, and agreements and the imposition of tariffs that affect our products or operations, including potential new tariffs that may be imposed and our ability to mitigate with respect to future operations, products and services, and statements regarding future performance. Actual results may differ materially in the future from those reflected in forward-looking statements contained in this document, based on a number of important factors and risks, which are more specifically identified in the Company’s most recent U.S. Securities and Exchange Commission (the “SEC”) filings. Further information regarding these risks, uncertainties and other factors are included in the Company’s most recent Annual Report on Form 20-F filed with the SEC and in its other filings with the SEC.

Contacts:

In Taiwan

Jesse Huang

ChipMOS TECHNOLOGIES INC.

+886-6-5052388 ext. 7715

IR@chipmos.com

In the U.S.

David Pasquale

Global IR Partners

+1-914-337-8801

dpasquale@globalirpartners.com

 

View original content:https://www.prnewswire.com/news-releases/chipmos-schedules-second-quarter-2026-financial-results-semiannual-conference-call-302831885.html

SOURCE ChipMOS TECHNOLOGIES INC.

Continue Reading

Trending